期刊
GENES & DEVELOPMENT
卷 35, 期 17-18, 页码 1256-1270出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.348662.121
关键词
DNA repair; nucleotide excision repair; translesion synthesis; Y family DNA polymerases; cisplatin intrastrand cross-links; Rev1
资金
- National Institutes of Health [R01 GM126087]
Chemotherapy with cisplatin is limited by its toxicity and risk of secondary malignancies. Targeting translesion synthesis (TLS) mechanisms in cancer cells, as opposed to normal cells, can exacerbate the toxicity and tumorigenicity of cisplatin-based chemotherapeutics.
Chemotherapy with cisplatin becomes limiting due to toxicity and secondary malignancies. In principle, therapeutics could be improved by targeting translesion synthesis (TLS) polymerases (Pols) that promote replication through intrastrand cross-links, the major cisplatin-induced DNA adduct. However, to specifically target malignancies with minimal adverse effects on normal cells, a good understanding of TLS mechanisms in normal versus cancer cells is paramount. We show that in normal cells, TLS through cisplatin intrastrand cross-links is promoted by Pol eta- or Pol(iota)-dependent pathways, both of which require Rev1 as a scaffolding component. In contrast, cancer cells require Rev1-Pol zeta. Our findings that a recently identified Rev1 inhibitor, JH-RE-06, purported to specifically disrupt Rev1 interaction with Pol zeta to block TLS through cisplatin adducts in cancer cells, abrogates Rev1's ability to function with Y family Pols as well, implying that by inactivating Rev1-dependent TLS in normal cells, this inhibitor will exacerbate the toxicity and tumorigenicity of chemotherapeutics with cisplatin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据